Meridian Funds, managed by ArrowMark Partners, outperformed the Russell 2500 Growth Index in Q2 2024. The top holding, Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), showed promising growth potential with a one-month return of 1.